A Robust N-Terminal Pro-Brain Natriuretic Peptide Assay for Clinical Diagnosis of Heart Failure in Elderly Patients

被引:0
作者
Xue Gong
Jiangling Wu
Jiajia Zhang
Zhongwei Jiang
Yi Wang
Pu Zhang
机构
[1] Chongqing Normal University,Engineering Research Center for Biotechnology of Active Substances (Ministry of Education), Chongqing Key Laboratory of Green Synthesis and Applications, College of Chemistry
[2] Chongqing Medical University,Chongqing Research Center for Pharmaceutical Engineering, College of Pharmacy
[3] University Town Hospital of Chongqing Medical University,Department of Clinical Laboratory
来源
Journal of Analysis and Testing | 2024年 / 8卷
关键词
NT-proBNP; Graphene oxide; Aptamer; Heart failure; Clinical diagnosis;
D O I
暂无
中图分类号
学科分类号
摘要
Heart failure (HF) is a clinical hallmark of cardiovascular syndrome leading to substantial morbidity, repeated hospitalization, and enormous healthcare expenditure. As elderly populations continue to increase, biomarker-guided diagnosis and treatment for age-related cardiac decline have become essential. Accumulating evidence demonstrates that N-terminal proBNP (NT-proBNP) can provide a unique window into the diagnosis and risk stratification with HF. Herein, a simple yet robust aptasensor is developed for on-site recognizing the NT-proBNP by its targeting aptamer, thus achieving the accurate diagnosis of HF. This aptasensing system is prepared by absorbing the fluorophore-labeled aptamer strand onto the graphene oxide (GO), leading to efficient quenching without possible off-site signal leakage. The aptamer strand can specifically identify target NT-proBNP molecules via a versatile conformational transformation, resulting in the desorption of the aptamer-NT-proBNP complexes from GO and re-generation fluorescence signal, thus allowing sensitive detection of NT-proBNP in 37 clinical blood samples. Taking advantage of the high specificity of aptamer-guaranteed recognitions of NT-proBNP, this aptasensor system readily achieves better diagnostic performance for HF than commercially adopted chemiluminescence immunoassay (Siemens, CLIA) in hospitals in terms of accuracy (89.2% vs 83.8%), specificity (89.5% vs 84.2%), and positive predictive value (88.9% vs 83.3%). This work provides a stable option for the diagnosis and treatment of elderly HF-related diseases in clinics.
引用
收藏
页码:74 / 82
页数:8
相关论文
共 271 条
  • [1] Law YM(2021)Diagnosis and management of myocarditis in children Circulation 144 e123-e135
  • [2] Lal AK(2020)Epidemiology of heart failure Eur J Heart Fail 22 1342-1356
  • [3] Chen S(2010)Natriuretic peptides in heart failure: should therapy be guided by BNP levels Nat Rev Cardiol 7 13-20
  • [4] Čiháková D(2005)Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis Circulation 112 527-534
  • [5] Cooper LT(2020)A lipid-nanopillar-array-based immunosorbent assay Adv Mater 32 2001360-1117
  • [6] Deshpande S(2021)Defect-rich CoOOH nanorings: a biocompatible and cost-efficient material for clinical diagnosis of children heart failure Chem Eng J 426 1110-13868
  • [7] Justin G(2020)A chemiluminescence immunoassay for the detection of NT-proBNP Anal Biochem 611 13797-914
  • [8] Wortmann LG(2017)Development of a BNP1-32 immunoassay that does not cross-react with proBNP Clin Chem 63 910-248
  • [9] Robinson JD(2021)Self-assembling nucleic acid nanostructures functionalized with aptamers Chem Rev 121 240-489
  • [10] Towbin JA(2022)A novel adenosine detection platform using 2-AP modified DNA and aptamer Chin J Anal Lab 41 482-7565